Internship - Chemical Biology jobs in United States
cer-icon
Apply on Employer Site
company-logo

Novo Nordisk · 15 hours ago

Internship - Chemical Biology

Novo Nordisk is a global pharmaceutical company focused on life science innovation. The Chemical Biology intern will participate in technological development activities and experiments related to a DNA-Encoded Library affinity screening platform, contributing to meaningful project work over a ten-week internship program.

BiotechnologyHealth CareMedicalPharmaceutical
check
Growth Opportunities
badNo H1Bnote

Responsibilities

Participate in technological development activities and experiments relating to a DNA-Encoded Library (DEL) affinity screening platform
Generate and optimize an SOP and/or collect sequencing data that will inform future DEL library designs

Qualification

Molecular biology techniquesProtein sciences applicationsDNA-Encoded Library (DEL)Microsoft Office ToolsProject managementInterpersonal communicationSelf-motivationAttention to detailFlexibilityAdaptability

Required

Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc

Preferred

An in progress undergraduate or graduate degree in Chemistry, Biochemistry, Biology, or a related discipline preferred

Company

Novo Nordisk

company-logo
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.

Funding

Current Stage
Public Company
Total Funding
$22M
2018-12-05Post Ipo Equity· $22M
1981-07-09IPO

Leadership Team

leader-logo
Lars Fruergaard Jørgensen
President and CEO
linkedin
leader-logo
Lars Sorensen
President & CEO
Company data provided by crunchbase